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The presence of surface membrane immunoglobulin (SmIg)  ~ detected by im- 
munofluorescent staining has been the most frequently used method for distin- 
guishing B lymphocytes from T lymphocytes (1). However, a substantial amount 
of SmIg found on B cells is not an integral part of the membrane but represents 
IgG bound through Fc receptors (2-4). Thus far, nonlabile, nonimmunoglobulin 
human B-lymphocyte antigens have not been well characterized. Recently we 
reported on rabbit antisera raised to papain digests of human malignant spleen 
cell membranes which appeared to detect leukemia-associated antigens (5). By 
complement (C)-dependent cytotoxicity both chronic and acute leukemia cells 
were positive,  although  the  majority of unfractionated normal  lymphocytes 
appeared negative. This report concerns further testing of the antisera using 
purified subpopulations of lymphocytes as targets and immunofluorescent-stain- 
ing techniques to detect minor populations of positive cells. From these tests it 
appears  that the antisera are detecting a  nonimmunoglobulin B-lymphocyte 
antigen that  is  expressed by the majority of leukemia cells,  including both 
lymphocytic and myelocytic subclasses. 
Materials and Methods 
Antisera.  Antisera with B-cell specificity were produced by immunization with papain digests 
of cell membranes of spleens from patients with hairy cell leukemia, histiocytic and lymphocytic 
lymphoma and Hedgkin's disease, and a normal donor.  The method of antigen solubilization has 
been described before (5). Briefly, fresh or frozen spleen tissue was cut into small pieces with 
scissors and then homogenized with a vortex homogenizer. Large cellular debris was removed by a 
low centrifugation step  (1,500 g).  Membrane fragments were recovered from the supernate by 
ultracentrifugation at 80,000 g for 90 min (no. 40 rotor; Beckman Instruments, Inc., Spinco Div., 
Palo Alto, Calif.).  The crude membrane pellet was washed with 0.15 M NaCl-10 mM Tris, pH 7.2 
(Tris-NaC1 buffer)  and then resuspended in water at 30 mg proteirdml. This suspension was then 
digested with an equal vol of crude papain  (Sigma Chemical Co.,  St.  Louis, Mo.) at 0.5 U/rag 
protein in 0.28 M NaC1-20 mM Tris, pH 8.6, containing 0.1 M cysteine. After incubation at 37°C for 
1 h, a 0.5 M iedoacetic acid solution (neutralized to pH 7.6) was added to a final concentration of  0.1 
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M. The undigested membrane was removed by ultracentrifugation at 80,000 g  for 60 min. The 
supernate was dialyzed against Tris-NaC1  buffer and stored  at  -90°C.  Sodium deoxycholate 
(0.5%)-solubilized membranes were also used to produce antiserum which had B-cell specificity. 
The soluble membrane extract was emulsified with complete  Freund's adjuvant and injected 
intradermally into the back and subcutaneously  into the foot pads of New Zealand white rabbits. 
A booster injection was given 4 wk later and after 2 more wk the animal was sacrificed. 
Cells.  Lymphocytes  and leukemia cells were isolated from heparinized peripheral blood by 
Ficoll-Hypaque density gradient centrifugation. B-cell-enriched and T-cell-enriched lymphocyte 
populations were isolated from 115 normal unrelated Caucasians. The B-cells were isolated from 
total lymphocytes by rosette formation of the T-cells with neuraminidase-treated  sheep erythro- 
cytes,  and relayering on Ficoll-Hypaque. After centrifugation  the rosetted T-cells sedimented to 
the bottom of the tube and the B-cells remained at the interface. The T-cells were recovered  by 
lysis of the sheep erythrocytes with hypotonic Hanks' balanced salt solution. The proportion of the 
B lymphocytes in the B-cell-enriched population of some samples was measured by fluorescent 
staining of surface immunoglobulin  using polyvalent rabbit antihuman immunoglobulin.  T-cell 
contamination  was less then 5%. The B-cell-enriched  and T-cell-enriched  lymphocyte suspensions 
were adjusted to 2.0 x  106/ml in McCoy's medium. 
The type of leukemia and the number  of leukemia cells present were determined by morphologi- 
cal examination. Relapse patients had high abnormal peripheral leukocyte counts; those patients 
in remission had  less than 5%  abnormal cells  in the bone marrow aspirates.  Bone marrow 
specimens were obtained by aspiration of the posterior superior iliac spine and leukocytes were 
freed of erythrocyte contamination  by hemagglutination and hypotonic shock. 
B-Lymphoblastoid  Cell Lines.  Daudi, Raji, P3 HR1K, BJAB, and Ramos were derived from 
patients with Burkitt's lymphoma; IM101 and Laim were derived from peripheral blood of patients 
with infectious mononucleosis; 6410, 8866, 4265, LA256, LA190, CCRM-SB, and 8392 from leuke- 
mia patients; and F265 and NC37 from normal donors. T-lymphoblastoid  cell lines MOLT 4, MOLT 
3,  CCRF-HSB,  CCRF-CEM,  and 8402 were  derived from  acute lymphocytic leukemia (ALL) 
patients. CCRM-SB and CCRF-HSB,  8402, and 8392 are paired B and T lines derived from the 
same donors. 
Cytotoxicity Test.  Antisera were judged positive when 1 ~l lysed more than 80% of 2,000 target 
cells after 60 min in the presence of 5 ftl of rabbit C. Less than 10% dead cells was considered a 
negative reaction. Cell lysis was measured by the eosin-dye  exclusion technique (6). Normal 
human sera or preimmunized rabbit sera were used as negative controls. 
Soluble antigens in sera or membrane extracts were detected by inhibition  of cytotoxicity.  1 pl 
of inhibitor  was added to 1 ~1 of antisera at its end point; after 30 min, target cells were added and 
then C as described above. 
Immunofluorescence.  2  ×  106 target cells  were incubated at 22°C for 30 min with antisera 
diluted 1:200 in phosphate-buffered  saline. After washing three times in McCoy's medium supple- 
mented with 0.5% fetal calf serum the cells were reincubated for 30 min with 100 pl fluorescein- 
conjugated goat antirabbit IgG (Meloy Laboratories Inc., Springfield, Va.) at a dilution of 1:100. 
After washing three times to remove the excess fluorescein reagent, the cells were examined with 
a Leitz orthoplan fluorescein microscope (E. Leitz, Inc., Rockleigh,  N. J.). 
Under ultraviolet light, positive cells  showed bright membrane immunofluorescent staining 
(Fig. 1), whereas negative cells appeared completely dark. Controls of the goat conjugate alone 
and preimmunized rabbit serum were negative. 
Results 
Of 27 rabbits immunized with papain digests of malignant spleen membranes 
from lymphoma patients (and 1 normal spleen) 25 produced antisera which had 
considerably higher C-dependent cytotoxicity titers against B  lymphocytes than 
against T  lymphocytes  (Table I).  Without  prior  absorption the  antisera  had 
titers ranging from  1:64  to  1:32,000  against B  cells and most leukemia  cells, 
whereas in most cases the undiluted sera were completely negative against T 
cells. Five sera had low titers (1:8 or lower) against T  cells. One rabbit (no. 112) 
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TABLE  I 
C-Dependent Cytotoxicity Titers of Various Rabbit Antisera against Normal T 
Lymphocytes  and Normal B Lymphocytes  or Leukemia Target Cells 
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Rabbit 
Source of Immunogen  Cytotoxicity titers* 
Patient  Diagnosis  T lymphocyte  B lymphocyte/ 
leukocyte cell 
63  AC  Histiocytic  lymphoma  0  128 
64  AC  Histiocytic  lymphoma  4  1,024 
66  AC  Histiocytic  lymphoma  0  512 
68  AC  Histiocytic lymphoma  0  1,024 
69  AC  Histiocytic  lymphoma  8  512 
70  AC  Histiocytic lymphoma  8  2,048 
71  AC  Histiocytic lymphoma  0  10,000 
74  AC  Histiocytic lymphoma  0  512 
75  AC  Histiocytic lymphoma  0  512 
77  AC  Histiocytic lymphoma  8  4,000 
78  AC  Histiocytic lymphoma  0  1,500 
79  AC  Histiocytic lymphoma  0  400 
80  AC  Histiocytic lymphoma  0  256 
85  DK  Lymphocytic lymphoma  0  64 
86  DK  Lymphocytic lymphoma  0  64 
90  MO  Hodgkins disease  0  256 
91  MO  Hodgkins disease  0  256 
93  SB  Hairy cell leukemia  0  256 
94  SB  Hairy cell leukemia  0  256 
97  UK  Normal  0  256 
98  PD  Histiocytic  lymphoma  0  32,000 
99  IK  Histiocytic lymphoma  0  0 
105  PD  Histiocytic lymphoma  4  512 
107  PV  Hodgkins disease  0  0 
111  AC  Histiocytic  lymphoma  0  256 
112  AC  Histiocytic lymphoma$  32  4,000 
120  AC  Histiocytic  lymphoma  0  256 
* Average titer against minimum of four cells. 
Sodium deoxycholate preparation. 
produced  antisera  with  anti-B-cell  activity.  This  serum,  however,  had  more 
activity against T  cells than those produced by papain-solubilized antigens. 
Table II shows the cytotoxic reactivity of the antisera from rabbits 63, 68, and 
98, tested separately against various normal and malignant lymphoid cells. All 
three antisera gave identical results showing selectivity for B  cells and certain 
leukemia cells.  T  and  B  lymphocytes were isolated from 115  different normal 
healthy  donors.  In all  cases these  undiluted  sera were completely unreactive 
against the T  cells,  although the  same sera showed high titers against the B- 
cell-enriched populations from the same donors.  Other normal peripheral blood 
cells tested, 56 granulocytes, 5 erythrocytes, and 3 PHA blasts, were negative. 
Leukemia cells from the majority of patients with active disease were positive. 
Of 40  cases  of acute  myelocytic leukemia  (AML),  blast  cells  from 30  of the 
patients  reacted  with  the  antisera,  whereas  10  did  not.  To  summarize  the 
reactivity against leukemia cells: about 70% of AML, chronic myelocytic leuke- 
mia (CML), and ALL cells and seven out of eight chronic lymphocytic leukemia 170  B-CELL ANTIGENS  EXPRESSED BY LEUKEMIA  CELLS 
TABLE II 
C-Dependent Cytotoxicity of  Rabbit A ntisera 63, 68, and 98 against Normal Blood Cells, 
Leukemia Cells, and Cultured Lymphoblastoid  Cell Lines 
Cell type  No. of cells tested  No. positive  Positive 
% 
T lymphocytes  115  0  0 
B lyrnphocytes  115  115  100 
Granulocytes  56  0  0 
Erythrocytes  5  0  0 
AML  4O  30  75 
ALL  41  28  68 
CML  13  9  69 
CLL  10  9  9O 
Phytohemagglutinin blasts  3  0  0 
T-cell lines*  5  0  0 
B-cell lines$  16  16  100 
* Molt 4, Molt 3, CCRF-HSB, CCRF-CEM, and 8402. 
Daudi, Raji, P3HR1K, BJAB, Ramos, IM101, Laim, 6410, 8866, 4265, LA256, LA190, CCRM-SB, 
8392, F265, and NC37. 
(CLL) cells reacted with the rabbit antisera. Therefore, the antigen concerned  is 
expressed by a majority but not all leukemia cells. However, those which were 
positive did include both the lymphocytic  and myelocytic  subclasses of  leukemia. 
The reactivity of the sera against cultured lymphoblasteid lines (Table II) 
supports the conclusion obtained using uncultured cells, namely that the anti- 
sera are reacting with an antigen found on B cells but not T cells.  All 16 lines 
tested with B-cell characteristics  were positive irrespective of whether they were 
derived from normal or malignant sources, whereas 5 out of 5 T-cell lines and a 
myeloid line, K562, were negative. In two cases B and T lines were derived from 
the same patient; the B lines reacted, whereas the T lines did not. The titers 
against cultured B lines were approximately the same as those against fresh B 
lymphocytes and cultured leukemia cells. 
The specificity of the antispleen antisera was also determined by immunoflu- 
orescent  staining  using  a  double  antibody  technique  with  goat  antirabbit 
gamma globulin fluorescein conjugate as the second layer. Fig. 1 shows the type 
of strong  membrane staining  obtained with  positive  cells;  unreactive cells 
showed no fluorescent staining. The percentages of immunofluorescent-positive 
cells present in various preparations of cells from blood and bone marrow are 
given in Table III. The numbers of positive cells found in total peripheral blood 
lymphocyte  preparations from 50 healthy donors ranged from 6 to 15%, which is 
within the range generally accepted for the percentage of B cells. As expected, 
the percentage of positive cells in B-enriched lymphocyte  preparations increased 
significantly (to 48-85%) while T-lymphocyte preparations, granulocytes, and 
platelets were completely negative. The immunofluorescent-staining  technique 
was again able to distinguish between two groups of leukemia patients: those 
with blast cells positive to the antisera and those with negative blast cells. 
Peripheral blood  and bone marrow preparations from positive patients with 
active leukemia had 30-95% reactive cells. A later table (Table VII) will show 
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FIG.  1.  Immunofluorescent staining of leukemia cells using rabbit anti-B-cell antisera 
followed by goat antirabbit gamma globulin conjugate. 
TABLE III 
Immunofluorescent  Staining of Various Normal and Malignant Blood 
Cells with Antispleen Sera 
Target cell  No. Cases  Positive  cells 
Normal peripheral lymphocytes  50 
B-rich normal lymphocytes*  9 
T-rich  normal lymphocytes  6 
Normal granulocytes  4 
Platelets  4 
Active$ leukemic peripheral leukocytes  9 
Active* leukemic bone marrow  15 
Remission leukemia bone marrow  61 
Normal donor bone marrow  7 
% 
6-15 
48-85 
0 
0 
0 
40-95 
30-95 
0-4 
0-4 
* Less than 5% erythrocyte-rosetting cells. 
* Positive cases with high blast cell counts. 
in blood and bone marrow from these patients. A group of approximately 25% of 
the patients had leukemia blast cells which did not fluoresce. 
Bone marrow preparations from 61 leukemia patients in remission and from 
normal donors had low numbers of positive cells (0-4%). Whether these positive 
cells are mature B cells or immature precursor cells has not been determined. 
It has been observed that nonspecific binding of antibody molecules to B cells 
can occur through Fc receptors (3). In order to eliminate the possibility that this 
kind of binding is involved, immunofluorescent-staining studies using F(ab')2 
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TABLE  IV 
Immunofluorescent Staining of Normal Peripheral  Blood Lymphocytes with Rabbit 
Antispleen Cell Antiserum (98), F(ab')2 Fragments of Serum 98 and Goat Antihuman 
Gamma Globulin Antisera 
Antisera  Target cells  Positive 
% 
98  Peripheral blood lymphocytes  11, 8,  14, 12, 6,  13 " 
98  B-enriched lymphocytes  85, 48, 76, 76, 67, 49 
98 F(ab')2  B-enriched lymphocytes  81, 71, 52 
Antihuman ~G  B-enriched lymphocytes  32, 45, 35, 51, 56, 43 
percentage of  positive cells using F(ab')2 fragments was similar to that obtained 
with whole antisera indicating that binding through the  Fc receptor is  not 
involved. The finding that the antibody could not be removed by washing at 
37°C, which removes antibody molecules bound through the Fc region,  also 
supports this conclusion. 
It is clear from the above results that the antisera are not reacting with T 
lymphocytes  but it is not clear which of the subpopulations of the non-T cells are 
reacting. Table V shows that the numbers of B-rich cells that were positive to 
antihuman gamma globulin sera (SmIg-positive cells)  range from 32 to 56%, 
whereas those that are positive with the rabbit antispleen antisera (98) range 
from 48 to 85%. It appears that in any one B-cell preparation the number of cells 
positive for antiserum 98 always exceeded the number of SmIg-positive cells. In 
addition, experiments in which both antisera were used simultaneously indi- 
cated  that  the  SmIg-positive cells  were part  of the  population  positive  for 
antiserum 98. Therefore, it appears that the rabbit antispleen sera are reacting 
not only with a population of non-T, SmIg-positive cells (true B cells) but also a 
population of non-T, SmIg-negative cells. 
The presence of soluble B-cell antigen in serum and in spleen extracts could be 
detected by inhibition of the  cytotoxicity of the  antispleen antisera against 
leukemia cells.  Significant inhibition was obtained with 5 out of 17 sera from 
leukemia patients who had peripheral blast cells which were positive for the 
rabbit antisera (Table V).  4 of 17  sera from lymphoma patients also showed 
significant inhibition. The inhibiting titers of the positive sera were less than 
1:8. No inhibition was seen with serum from normal individuals, nonlymphopro- 
liferative cancer patients, and negative leukemia patients. 
The clinical course of leukemia could be followed by examining bone marrow 
samples  for immunofluorescent-positive cells using the  antispleen  antisera. 
Bone marrow samples from children with leukemia were examined before and 
after chemotherapy. The numbers of fluorescein-positive cells were found to 
correspond to the stage of the disease as determined by morphological examina- 
tion (Table VI).  In newly diagnosed cases, the number of fluorescein-positive 
cells in the bone marrow was high  (over 80%). After inducing remission by 
chemotherapy the numbers of positive cells decreased to 0-2%  which was in 
general agreement with the number of blast cells found at this time by morpho- 
logical examination. After relapse the increase of fluorescein-positive cells was 
again commensurate with the increased numbers of blast cells. 
Absorption experiments (Table VII) seem to rule out the possibility that the BILLING,  RAFIZADEH,  DREW,  HARTMAN,  GALE, AND  TERASAKI 
TABLE  V 
Detection of  Soluble B-CeU Antigen in the Serum of  Patients with 
Leukemia and Lymphoma 
Serum  No.  positive/no, tested 
Leukemia (+)*  5/17 
Leukemia (-)$  0/12 
Lymphoma  4/17 
Other cancers  0/6 
Normals  0/12 
* Serum from leukemia patients with peripheral blasts that were posi- 
tive to the rabbit antispleen antisera. 
Serum from leukemia patients with peripheral blasts that were nega- 
tive to the rabbit antispleen antisera. 
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TABLE  VI 
A  Comparison  of the Number of Blasts and lmmunofluorescent (IF)-Positive  Cells in 
Bone Marrow Aspirates from ALL Patients before and after Treatment 
Date  Patient  Treatment  Diagnosis  Blast  IF 
%  % 
2/18  GE  Untreated  ALL new case  87  95 
3/19  Chemotherapy  ALL remission  1  Neg. 
2/19  PR  Untreated  ALL new case  93  70 
3/25  Chemotherapy  ALL remission  3  2 
3/5  SJ  Untreated  ALL new case  97  80 
4/5  Chemotherapy  ALL remission  0  1 
5/30  Chemotherapy  ALL remission  0  2 
4/11  CH  Untreated  ALL new case  66  60 
7/12  Chemotherapy  ALL remission  0  Neg. 
4/11  JW  Untreated  ALL new case  46  46 
6/24  Chemotherapy  ALL partial relapse  17.5  19 
7/1  Chemotherapy  ALL partial relapse  17.0  15 
rabbit antisera contain two specificities, one directed against normal B  cells 
and the other against leukemia cells. B lymphocytes  and T lymphocytes  isolated 
from the same normal healthy donor (no. 238) and AML cells 812 were used to 
absorb rabbit serum 68. The absorbed sera were retested against five different 
B-cell preparations, three AML, and one ALL cell. In general, 106 B-lymphocyte 
238 cells were able to remove the activity of serum 68 against both B cells and 
leukemia cells.  10  s AML 812  cells were also able to remove both anti-B and 
antileukemia activity. T-cell preparation 812 was not able to remove either the 
anti-B or antileukemia activity of serum 68.  l0  s AML 694  cells removed the 
activity of  antiserum 63 against both AML 694 and CLL 227 suggesting that they 
express common antigens. 
Discussion 
Rabbit  antisera  raised  to  papain  digests  of human  spleen  cell  membrane 
appear to recognize a previously uncharacterized B-cell antigen.  The sera were 174  B-CELL  ANTIGENS  EXPRESSED  BY  LEUKEMIA  CELI.~ 
TABLE  VII 
Cytotoxicity of Rabbit Anti-B-Cell Sera 68 and 63 Absorbed with B Lymphocytes and 
Leukemia Cells 
Target cells 
Serum  Absorbing  cells  B  lymphocytes  Leukemia  cells 
463*  547  636  712  840  AML 553  ALL 640  AML  112  AML 812 
68  Unabsorbed  +  +  +  +  +  +  +  +  + 
68  10  ~ B  lymphocyte8 238*  +  +  +  +  +  +  +  +  + 
68  10  ~ B  lymphocytes  238  -  ±  -  -  - 
68  1@ T  lymphocytes  238  +  +  +  +  +  +  +  +  + 
68  10  ~ T  lymphocytes 238  +  +  +  +  +  +  +  +  +_ 
68  10  ~ AML  812  +  +  +  +  +  +  +  +  + 
68  I0  ~ AML 812  -  - 
AML  694  CLL  227 
63  Unabsorbed  +  + 
63  10  ~ AML 694 
63  10  ~ CLL 227 
+  >80%  kill 
-  <20%  kill 
+_  30-70%  kill 
* These numbers  refer to the cell donor. 
strongly positive by both cytotoxicity and immunofluorescence tests against 
peripheral  blood  B  cells  and  cultured B-cell  lines  but  completely negative 
against normal and cultured T cells, granulocytes, erythrocytes, and platelets. 
Most of the T and B lymphocytes  and two of the T- and B-cell lines were paired, 
i.e., derived from the same donor. There were large differences in the titers 
between the T and B cells which would tend to rule out reactivity against anti- 
gens such as HLA that are present on T cells. 
Leukemia cells from approximately 70%  of patients with ALL, AML,  and 
CML,  and seven of eight patients with CLL were also positive. Although it is 
possible that the antisera contain antibodies against leukemia-associated anti- 
gens that are distinct from antibodies against normal B lymphocytes, most of 
the evidence appears to be against this: (a) absorption experiments with B cells 
and  leukemia cells  indicate that  there  is  a  common antigen  involved;  (b) 
antisera with leukemia activity can be raised to normal spleen extracts; and (c) 
the antisera have the same titers against B cells and against leukemia cells. 
Therefore, it appears that the antisera made to papain digests of spleen mem- 
branes are recognizing a normal B-lymphocyte antigen which is also expressed 
by both lymphocytic and myelocytic leukemia cells. 
Several previous studies have shown that leukemia cells from the majority of 
cases of ALL,  AML,  and  CML  are  null  cells  lacking known B-  and T-cell 
markers such as Fc and C3 receptors, surface immunoglobulins, and receptors 
for sheep erthyrocytes (7,  8).  From these studies it appears that the "nulr' 
leukemia cells express the B-cell antigen defined by our rabbit antisera. This 
group rather surprisingly includes the myeloid leukemias. It is not clear why BILLING,  RAFIZADEH,  DREW,  HARTMAN,  GALE,  AND  TERASAKI  175 
cells derived from the myeloid series should express an antigen that is found on 
mature B lymphocytes but that is not found on mature granulocytes. However, 
although the antigen is expressed by B lymphocytes, it should not necessarily be 
considered to indicate that myelocytic leukemias are of B-cell origin. Most CLL 
cells, however, are of B-cell origin (9) which makes it less surprising that seven 
out of eight CLL cells reacted with the antisera (the negative CLL appeared to 
be one of the rare CLL's expressing T-cell characteristics). Whether or not the 
negative ALL, AML, and CML cells have T-cell characteristics is not presently 
clear. However, in the case of childhood ALL, this appears to be the case. The 
proportion of patients with unreactive ALL blasts  (30%) is approximately the 
same as  the proportion  of T-cell ALL's  characterized by erythrocyte rosette 
formation (7). In addition, we have found that all those leukemia cells positive 
for the rabbit anti-B-cell serum are also positive for human anti-B-cell alloanti- 
sera. 2 A study by Fu et al. has shown that the non-B, non-T ALL appear to be 
those that react with the human anti-B-cell sera, whereas the T-cell ALL's do 
not (10). 
The reactivity of cultured lymphoblastoid cell lines with the antispleen anti- 
sera confirms its specificity for a B-cell antigen. All 14 B-cell lines tested were 
positive, irrespective of whether the cells were derived from normal or malig- 
nant sources; 5  T-cell lines and one myeloid cell were negative.  One of the 
positive cell lines was Daudi,  a  cell on which we and others (11) have been 
unable to detect HLA antigens or beta2 microglobulin. The reactivity of this cell 
would suggest that beta2 microglobulin is not associated with the B antigen in 
the manner that it is associated with HLA antigens (12). 
All of the B-cell lines that react with the rabbit anti-B-cell sera also react with 
human anti-B-cell sera directed against Ia-like antigens. Therefore it is possible 
that the B antigen is associated with part of these Ia-like molecules. Because the 
rabbit sera reacted with all normal and cultured B cells thus far tested, they are 
probably not reacting with the Ia antigenic site itself which is polymorphic but 
perhaps a common region of the same molecule. The fact that human anti-B-cell 
sera can be specifically blocked with rabbit anti-B F(ab')2 fragments would sup- 
pert this conclusion which is considered in detail in another publication. 2 
From immunofluorescent-staining studies on peripheral blood lymphocytes 
the antisera appeared to be reacting with a larger population of cells than those 
expressing SmIg. However, the number of positive cells seen when the anti-B- 
cell antisera were used alone was the same as that when both anti-B-cell and 
antihuman gamma globulin were used together. Therefore it appears that SmIg 
cells are positive and also, in addition, a population of non-T, non-SmIg cells are 
positive.  Whether or not these positive non-T,  non-SrnIg cells are null  cells 
(SmIg negative,  Fc  receptor positive)  is  not yet clear.  However,  the anti-B 
antisera are cytotoxic for the effector cell in the LDA test which suggests that 
they may react with  null  cells because these cells have been implicated as 
lymphocyte-dependent antibody effector cells (13). 
Several authors have described both rabbit (14, 15) and human (16) antisera 
2 Billing, R. J., A. Ting, and P. I. Terasaki. 1976. Human B-lymphocyte antigens expressed by 
lymphocytic and myelocytic leukemia cells.  H.  Detection by human anti-B-cell alloantisera. 
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that were cytolytic for leukemia cells but not normal cells.  However, in most 
cases these sera were not tested for reactivity against normal B-lymphocyte 
preparations. From our studies it would seem that most leukemia cells express 
B-cell antigens and therefore antisera that appear to be leukemia-specific  might 
in fact be reacting against B-cell  antigens. It appears that papain extracts of 
beth fresh or cultured B-lymphoid cells (5) produce antisera that react with B 
lymphocytes and most leukemia cells.  Recently Cresswell and Geier (17) and 
Thieme and Colombe (18) produced rabbit antiserum to papain extracts of the 
human B-cell line RPMI 4265 which reacted against peripheral B lymphocytes 
(17) and to B-lymphoid cell lines (18). Although a direct comparison between 
sera has not been made, it would seem most likely that beth these sera have 
similar specificities to the antisera described here. It is not clear whether or not 
rabbit anti-B-cell sera produced by immunization with whole cultured B-cell 
lines  (19) are  reacting  against  the  same  determinant.  Nonhuman primate 
antileukemia antisera  (15) appear to be  specific  for individual subclasses of 
leukemia and therefore different from the rabbit serum described here. 
Although the method used to solubilize spleen membrane antigens is the one 
generally used to solubilize HLA antigens, the antisera were not very reactive 
to HLA antigens. Cresswell and Geier (16) showed by immunoprecipitation that 
similar  antisera raised to  cultured B-cell  lines did appear  to  contain  some 
antibodies directed against HLA antigens and beta2 microglobulin in addition to 
antibodies against B-cell antigens. The reason for the lack of HLA activity in 
our sera is not yet clear; however, it is possible that the malignant spleens which 
we used as a source of antigen have more B antigen than HLA. It is also possible 
that the B antigen is more immunogenic than HLA. 
Because the anti-B-cell antisera described here do not require absorption, 
sufficient  quantities could become available for general use as an immunological 
diagnostic tool which might expand our capabilities for studying subpopulations 
of  human lymphoid cells. The fact that soluble B-cell antigen was detected in the 
serum of leukemia and lymphoma patients might provide the basis of more 
sensitive diagnostic aids for these lymphoproliferative diseases. 
Perphaps the most significant finding here is that AML,  ALL,  and CML 
appear to be divisible into the B-cell antigen-positive type (about 70%) and the 
non-B-cell antigen-negative type on the basis of the rabbit antiserum. The fact 
that the myeloid leukemias are indistinguishable from the lymphoid leukemias 
in this respect is surprising. The B-cell antigen is apparently present on blast 
cells of beth the lymphoid and myeloid series, but,  significantly, not in the 
cultured T lymphoblasts. The clinical significance is not yet clear, although beth 
with respect to etiology and treatment, a difference should emerge. 
Summary 
A previously uncharacterized  human B-lymphocyte  antigen has been detected 
by rabbit  antisera  raised  to  papain  digests  of spleen cell membranes.  The 
unabsorbed sera reacted in both cytotoxicity and immunofluorescent  tests with 
normal B lymphocytes and cultured B-cell lines but not with normal T lympho- 
cytes or cultured T-cell lines. The cytotoxicity  titers against B cells were as high 
as 1:32,000, whereas the same sera undiluted were negative against T cells.  By BILLING,  RAFIZADEH,  DREW,  HARTMAN,  GALE,  AND  TERASAKI  177 
immunofluorescent staining 6-14% of unfractionated normal lymphocytes and 
48-85%  of B-rich  lymphocyte preparations  were  positive.  Normal  peripheral 
blood  granulocytes,  platelets,  erythrocytes,  and  phytohemagglutinin  blasts 
were negative. The antisera reacted with the same high titers against leukemia 
cells from approximately 70% of the patients with acute lymphocytic leukemia, 
acute  myelocytic leukemia,  chronic myelocytic leukemia,  and  seven of eight 
cases  of chronic lymphocytic leukemia.  From  absorption  studies  it  appeared 
that the same  antigen  was  being expressed by leukemia  cells and  normal  B 
lymphocytes. Using immunofluorescent staining the anti-B-cell antisera were 
able  to  detect  positive  leukemia  cells  in  the  bone  marrow  of patients  with 
advanced leukemia and to monitor the elimination of these cells after chemo- 
therapy. Soluble B-cell antigen was found in the serum of some leukemia and 
lymphoma patients but not in normal serum. 
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